Inspire Medical Systems, Inc. Common Stock (INSP)

Inspire (INSP) Q1 2026 Earnings Call Transcript

Medical technology company Inspire Medical Systems (NYSE:INSP) beat Wall Street’s revenue expectations in Q1 CY2026, with sales up 1.6% year on year to $204....

Inspire (INSP) Q2 2025 Earnings Call Transcript

Medical technology company Inspire Medical Systems (NYSE:INSP) will be announcing earnings results this Monday afternoon. Here’s what to expect. Inspire Medi...

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff...

Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remember...

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have realized stron...

Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they strugg...

Shareholders of Inspire Medical Systems would probably like to forget the past six months even happened. The stock dropped 22.7% and now trades at $62.98. Th...

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Inspire Medical Systems (NYSE:INSP) and the rest of the medical devices & supplies - specialty stocks fared in Q4.

Shares of medical technology company Inspire Medical Systems (NYSE:INSP) fell 7.5% in the afternoon session after the release of a key inflation report revealed prices paid to U.S. producers rose more than anticipated in January. 

Shares of medical technology company Inspire Medical Systems (NYSE:INSP) jumped 19.7% in the afternoon session after reports revealed that the Centers for Medicare & Medicaid Services (CMS) is preparing to assign specific C-codes for the Inspire V device in the April 2026 Integrated Outpatient Code Editor (IOCE) update. 

Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.

Inspire Medical Systems’ fourth quarter was marked by robust revenue growth and improved operating margins, yet the market responded negatively due to heightened uncertainty around reimbursement for its Inspire 5 system. Management attributed the quarter’s performance to strong patient demand, successful rollout of Inspire 5, and disciplined cost controls, with CEO Timothy Herbert highlighting “a significant increase in the fourth quarter in social media activity” and expanded physician training. However, the looming changes in procedure coding and associated professional fee reductions created caution among investors and management alike.

A number of stocks jumped in the afternoon session after a softer-than-expected inflation report fueled hopes for interest rate cuts by the Federal Reserve. The January Consumer Price Index (CPI), a key measure of inflation, rose by 0.2%, which was less than economists had forecast, with the annual rate cooling to 2.4%. This encouraging data increased market expectations for the Fed to begin cutting interest rates as early as June. The news prompted a rally in Treasuries as their yields fell. While the market's reaction was initially described as a "bumpy ride" due to concerns in other sectors, the favorable inflation data ultimately helped calm Wall Street. Lower inflation is a key prerequisite for the central bank to ease its monetary policy, which is generally supportive of stock valuations.

Shares of medical technology company Inspire Medical Systems (NYSE:INSP) fell 8.7% in the morning session after the company's weak full-year revenue guidance overshadowed its strong fourth-quarter earnings report. 

Medical technology company Inspire Medical Systems (NYSE:INSP) reported Q4 CY2025 results topping the market’s revenue expectations, with sales up 12.2% year on year to $269.1 million. On the other hand, the company’s full-year revenue guidance of $975 million at the midpoint came in 2.7% below analysts’ estimates. Its non-GAAP profit of $1.65 per share was significantly above analysts’ consensus estimates.

Inspire Medical (INSP) Q4 2025 Earnings Transcript

Medical technology company Inspire Medical Systems (NYSE:INSP) reported Q4 CY2025 results beating Wall Street’s revenue expectations, with sales up 12.2% year on year to $269.1 million. On the other hand, the company’s full-year revenue guidance of $975 million at the midpoint came in 2.7% below analysts’ estimates. Its non-GAAP profit of $1.65 per share was significantly above analysts’ consensus estimates.

Medical technology company Inspire Medical Systems (NYSE:INSP) will be reporting results this Wednesday after market close. Here’s what to expect.

Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a high-risk, high-reward environment due to the lack of reliable analyst price targets.